Danaher Co. (NYSE:DHR) Shares Acquired by Journey Strategic Wealth LLC

Journey Strategic Wealth LLC raised its position in shares of Danaher Co. (NYSE:DHR) by 42.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 2,963 shares of the conglomerate’s stock after buying an additional 890 shares during the quarter. Journey Strategic Wealth LLC’s holdings in Danaher were worth $680,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after purchasing an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. raised its position in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares in the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new position in shares of Danaher during the 4th quarter valued at approximately $74,551,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 11.10% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $222.56 on Monday. Danaher Co. has a 12-month low of $221.34 and a 12-month high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $160.75 billion, a price-to-earnings ratio of 42.15, a price-to-earnings-growth ratio of 4.22 and a beta of 0.83. The business has a 50 day simple moving average of $235.40 and a 200 day simple moving average of $253.08.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.72% and a net margin of 16.33%. During the same period in the previous year, the business earned $2.09 earnings per share. On average, equities research analysts anticipate that Danaher Co. will post 8.15 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.49%. Danaher’s dividend payout ratio (DPR) is 20.45%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent analyst reports. Citigroup cut their price target on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a report on Thursday. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research note on Thursday, October 31st. JPMorgan Chase & Co. cut their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Guggenheim started coverage on Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.